Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01184820 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
A Phase 1 study of Hemophilia A, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 4
- Study locations
NCT01184820 is a Phase 1 study of Hemophilia A that has completed, run by Bayer. The registered enrollment target is 14 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01184820, a Phase 1 study of Hemophilia A, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to describe the pharmacokinetics (PK) of BAY94-9027(the test drug). Pharmacokinetics means that we will measure how well the study drug corrects the factor VIII levels in your blood and how long it takes for the levels to fall back to your baseline level. The study is also designed to determine if the pharmacokinetics of BAY94-9027 change following repeat dosing over 8 weeks, determine if BAY94-9027 is safe, tolerable, and effective for the treatment of severe hemophilia A and define the appropriate dose of BAY94-9027. Two doses of BAY94-9027 will be studied. The first 8 subjects enrolled in the study (cohort 1) will receive a low dose (25 IU/kg) and will be treated 2 days a week for 8 weeks (total of 16 doses). The second 8 subjects (cohort 2) will receive a higher dose and will be treated 1 day a week for 8 weeks (total 8 doses). All subjects will receive a single dose of rFVIII (Bayer Kogenate FS) to determine the PK by measuring blood levels for 2 days before they start the study drug BAY94-9027. Factor VIII blood levels for BAY94-9027 will be measured for 7 days after the first and last dose to see describe the PK. Safety \& tolerability assessment include vital signs, coagulation and hematological parameter, clinical chemistry, measurement of FVIII inhibitor and polyethylene glycol (PEG) antibodies will be done during the course of the study.
Conditions Studied
Interventions
- BIOLOGICAL BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- BIOLOGICAL BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))
Study Locations (4)
California
- - Davis
Massachusetts
- - Boston
Minnesota
- - Minneapolis
New York
- - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-10-13 |
| Est. Completion | 2011-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01184820
The ClinicalTrials.gov registry entry for NCT01184820 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (85% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 2 interventions - of which BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222) is the first listed.
NCT01184820 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01184820 about?
NCT01184820 is a clinical study titled "Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration". The purpose of this study is to describe the pharmacokinetics (PK) of BAY94-9027(the test drug). Pharmacokinetics means that we will measure how well the study drug corrects the factor VIII levels in your blood and how long it takes for the levels to fall back to your baseline level. The study is al...
What is the current status of trial NCT01184820?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2010-10-13. Estimated completion is 2011-10-10.
What conditions does trial NCT01184820 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT01184820?
The interventions under investigation include: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222) (BIOLOGICAL), BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01184820?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01184820 being conducted?
This trial has 4 study locations across California, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
-
ASC618 Gene Therapy in Hemophilia A Patients
RECRUITING · Phase 1
-
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RECRUITING · Phase 1
-
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy for Haemophilia A.
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.